Pharmaceutical - Pharmaceutical, North America, Anti-Arthritics/Rheumatics

1 to 25 of 51 results

Pfizer to appeal Court decision on Celebrex reissue patent

Pfizer to appeal Court decision on Celebrex reissue patent

13-03-2014

US pharma behemoth Pfizer confirmed today that the US District Court for the Eastern District of Virginia…

Anti-Arthritics/RheumaticsCelebrexLegalNorth AmericaPatentsPfizerPharmaceuticalUSA

US FDA approves Anika’s Monovisc for osteoarthritis pain of the knee

26-02-2014

US drugmaker Anika Therapeutics has received marketing approval for Monovisc from the US Food and Drug…

Anika TherapeuticsAnti-Arthritics/RheumaticsDePuyMonoviscNorth AmericaPharmaceuticalRegulationUSA

FDA advisory panel ambivalent on NSAID cardiovascular risk

FDA advisory panel ambivalent on NSAID cardiovascular risk

12-02-2014

The US Food and Drug Administration’s joint Arthritis Advisory Committee and Drug Safety and Risk Management…

Anti-Arthritics/RheumaticsBayerNaproxenNeurologicalNorth AmericaPfizerPharmaceuticalUSA

DMC clears Merck & Co’s Alzheimer’s drug MK-8931 development

DMC clears Merck & Co’s Alzheimer’s drug MK-8931 development

10-12-2013

The development program for MK-8931, a novel investigational oral beta-amyloid precursor protein site-cleaving…

Anti-Arthritics/RheumaticsFinancialFosamaxMerck & CoMK-8931NeurologicalNorth AmericaPharmaceuticalResearch

Health Canada clears AbbVie’s Humira for UC

Health Canada clears AbbVie’s Humira for UC

28-11-2013

In what is now the eighth indication in Canada for its top-selling drug Humira (adalimumab), US drugmaker…

AbbVieAnti-Arthritics/RheumaticsGastro-intestinalsHumiraNorth AmericaPharmaceuticalRegulation

Sanofi and Regeneron report positive Phase III results with sarilumab in RA

Sanofi and Regeneron report positive Phase III results with sarilumab in RA

22-11-2013

French drug major Sanofi (Euronext: SAN) and US partner Regeneron Pharmaceuticals (Nasdaq: REGN) have…

Anti-Arthritics/RheumaticsEuropeNorth AmericaPharmaceuticalRegeneronResearchSanofisarilumabUSA

Horizon Pharma gets US rights for Vimovo from AstraZeneca

Horizon Pharma gets US rights for Vimovo from AstraZeneca

19-11-2013

USA-based Horizon Pharma has entered into an agreement to acquire from Anglo-Swedish drug major AstraZeneca…

Anti-Arthritics/RheumaticsAstraZenecaHorizon PharmaLicensingNorth AmericaPharmaceuticalPozenVimovo

Genentech’s SC Actemra approved by US FDA for severe RA

Genentech’s SC Actemra approved by US FDA for severe RA

22-10-2013

Genentech has announced that the US Food and Drug Administration has approved a subcutaneous formulation…

ActemraAnti-Arthritics/RheumaticsGenentechNorth AmericaPharmaceuticalRegulationRoche

UCB’s Cimzia granted additional indication by US FDA

UCB’s Cimzia granted additional indication by US FDA

30-09-2013

UCB revealed today that the US Food and Drug Administration has approved its currently marketed drug…

Anti-Arthritics/RheumaticsCimziaNorth AmericaPharmaceuticalRegulationUCB

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

26-09-2013

The US Food and Drug Administration has approved changes to the prescribing information of the immune-suppressing…

Anti-Arthritics/RheumaticsArzerraBiogen IdecGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRituxanRoche

Enbrel and Humira remain the mainstay for first-line biologic rheumatoid arthritis treatment in USA

19-09-2013

The vast majority of patients in the USA treated with Amgen's (Nasdaq: AMGN) Enbrel (etanercept) and…

AbbVieAmgenAnti-Arthritics/RheumaticsEnbrelHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalXeljanz

Horizon Pharma in Duexis patent settlement

22-08-2013

Horizon Pharma (Nasdaq: HZNP) says it has entered into settlement and license agreements with Par Pharmaceutical…

Anti-Arthritics/RheumaticsDuexisGenericsHorizon PharmaNorth AmericaPar PharmaceuticalPatentsPharmaceutical

US FDA accepts Pennsaid 2% NDA for review

22-08-2013

The US Food and Drug Administration has accepted for filing US drugmaker Mallinckrodt's (NYSE: MNK) New…

Anti-Arthritics/RheumaticsGenericsMallinckrodtNorth AmericaNuvo ResearchPennsaidPharmaceuticalRegulation

Nuvo Research files law suit against Mallinckrodt

21-08-2013

Canadian specialty pharma company Nuvo Research (TSX: NRI) says it has commenced legal action against…

Anti-Arthritics/RheumaticsLegalLicensingMallinckrodtNorth AmericaNuvo ResearchPennsaidPharmaceutical

Ampio's osteoarthritis treatment shows key reduction in pain

14-08-2013

USA-based biopharma firm Ampio Pharmaceuticals (Nasdaq: AMPE) has announced positive results from its…

Ampio PharmaceuticalsAmpionAnti-Arthritics/RheumaticsNorth AmericaPharmaceuticalResearch

Nuvo's partner Mallinckrodt to resubmit osteoarthritis treatment to US FDA

24-07-2013

Canada's Nuvo Research (TSX: NRI) says that its licensing partner Mallinckrodt (NYSE: MNK) has successfully…

Anti-Arthritics/RheumaticsCovidienMallinckrodtNorth AmericaNuvo ResearchPennsaidPharmaceuticalRegulation

Simponi ARIA cleared by US FDA

19-07-2013

US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Biotech subsidiary has received US Food…

Anti-Arthritics/RheumaticsBiotechnologyJanssen BiotechJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi ARIA

Briefs: Added use for Theravance's Vibativ; approval sought for ViiV dolutegravir; FDA accepts Pfizer sNDA for Xeljanz

23-06-2013

USA-based Theravance (Nasdaq: THRX) says that the US Food and Drug Administration has approved the firm's…

Anti-Arthritics/RheumaticsAnti-viralsAntibiotics and Infectious diseasesBiotechnologydolutegravirNorth AmericaPfizerPharmaceuticalRegulationTheravanceVibativViiV HealthcareXeljanz

Therapy's induction of remission an attribute that most influences Rxing decisions in rheumatoid arthritis

20-06-2013

The majority of US and European rheumatologists surveyed by health care advisory firm Decision Resources…

AbbVieActemraAnti-Arthritics/RheumaticsEisaiEuropeHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalRocheTakeda PharmaceuticalsXeljanz

AbbVie/Eisai's Humira has best clinical profile among psoriatic arthritis treatments

03-06-2013

Based on clinical data and the opinions of interviewed thought leaders interviewed by health care advisory…

AbbVieAnti-Arthritics/RheumaticsAstellas PharmaBiotechnologyCimziaEisaiEuropeHumiraMarkets & MarketingNorth AmericaPharmaceuticalUCB

Novartis' Ilaris gets new indication of childhood arthritis from US FDA

10-05-2013

Swiss pharmaceutical major Novartis (NIVN: VX) said this morning (May 10) that the US Food and Drug Administration…

Anti-Arthritics/RheumaticsNorth AmericaPharmaceuticalRare diseasesRegulation

Merck & Co wins Fosamax federal bellwether trial over atypical femur fracture claims

30-04-2013

A US has jury found in favor of pharma giant Merck & Co (NYSE: MRK) in the Glynn versus Merck case in…

Anti-Arthritics/RheumaticsFosamaxLegalMerck & CoNorth AmericaPharmaceutical

Thought leader views on new osteoporosis and osteopenia treatments

05-04-2013

US and European primary care physicians (PCPs) agree that efficacy on hip fracture risk reduction is…

AMG-785AmgenAnti-Arthritics/RheumaticsBiotechnologyCDP-7851Eli LillyEuropeHealthcareMarkets & MarketingMerck & CoNorth AmericaodanacatibPharmaceuticalteriparatideUCB

Epratuzumab and Lupuzor have potential to offer improvements over Benlysta in reducing Lupus disease activity

04-04-2013

US and European rheumatologists surveyed by health care advisory firm Decision Resources indicate that…

Anthera PharmaceuticalsAnti-Arthritics/RheumaticsBenlystaBiotechnologyblisibimodepratuzumabEuropeGlaxoSmithKlineImmunomedicsImmuPharmaLupuzorMarkets & MarketingNorth AmericaPharmaceuticalUCB

1 to 25 of 51 results

Back to top